Rarity Bioscience superRCA technology assays

Wednesday, 12 March, 2025 | Supplied by: Beckman Coulter Australia


As part of a co-exclusive distribution agreement, Beckman Coulter Life Sciences will market and distribute Rarity Bioscience’s superRCA technology assays. The assays are claimed to accelerate the detection of mutations by using flow cytometry with logarithmically higher sensitivity compared to the current gold standard digital PCR (dPCR) method.

While traditional flow cytometry research analyses phenotypes, the platform combines a molecular assay based on rolling circle amplification and padlock probes with a flow cytometry readout for high sensitivity and specific multiplex detection of sequence variants, including single point DNA mutations. The assay offers high throughput, resulting in fast turnaround without the need for additional hardware, lowering the barriers to molecular research assays.

Online: www.beckman.com.au
Phone: 1800 060 878
Related Products

Amsbio Acepix FFPE tissue blocks

Amsbio has expanded its range of high-quality formalin-fixed, paraffin-embedded (FFPE) tissues...

Promega Paradyme 27GY STR System

The Paradyme 27GY STR System features a novel enzyme that reduces the most common type of...

Mercodia Insulin MBeads Assay

The assay is designed to offer high accuracy by specifically measuring human insulin while...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd